The Cigna Group

LSE:0A77 Stock Report

Market Cap: US$68.5b

Cigna Group Valuation

Is 0A77 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A77 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$1.08k
Fair Value
75.7% undervalued intrinsic discount
23
Number of Analysts

Below Fair Value: 0A77 ($262.84) is trading below our estimate of fair value ($1082.84)

Significantly Below Fair Value: 0A77 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A77?

Key metric: As 0A77 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0A77. This is calculated by dividing 0A77's market cap by their current earnings.
What is 0A77's PE Ratio?
PE Ratio11.1x
EarningsUS$6.15b
Market CapUS$68.49b

Price to Earnings Ratio vs Peers

How does 0A77's PE Ratio compare to its peers?

The above table shows the PE ratio for 0A77 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.9x
IDHC Integrated Diagnostics Holdings
14x21.03%US$328.4m
SN. Smith & Nephew
28.7x15.30%UK£10.5b
CTEC ConvaTec Group
28.3x15.29%UK£4.6b
FRE Fresenius SE KGaA
24.5x15.61%€27.2b
0A77 Cigna Group
11.1x4.85%US$68.5b

Price-To-Earnings vs Peers: 0A77 is good value based on its Price-To-Earnings Ratio (11.1x) compared to the peer average (23.9x).

Price to Earnings Ratio vs Industry

How does 0A77's PE Ratio compare vs other companies in the European Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0A77 11.1xIndustry Avg. 17.7xNo. of Companies9PE01224364860+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0A77 is good value based on its Price-To-Earnings Ratio (11.1x) compared to the European Healthcare industry average (17.7x).

Price to Earnings Ratio vs Fair Ratio

What is 0A77's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A77 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.1x
Fair PE Ratio49.2x

Price-To-Earnings vs Fair Ratio: 0A77 is good value based on its Price-To-Earnings Ratio (11.1x) compared to the estimated Fair Price-To-Earnings Ratio (49.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A77 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$262.84
US$332.96
+26.68%
8.07%US$378.00US$270.00n/a23
Oct ’26US$292.47
US$366.79
+25.41%
8.13%US$428.00US$300.00n/a23
Sep ’26US$301.65
US$367.87
+21.95%
7.87%US$428.00US$300.00n/a23
Aug ’26US$258.19
US$366.35
+41.89%
6.92%US$407.00US$300.00n/a23
Jul ’26US$335.10
US$375.34
+12.01%
5.30%US$407.00US$330.60n/a24
Jun ’26US$318.11
US$375.21
+17.95%
5.29%US$407.00US$330.60n/a24
May ’26US$338.99
US$363.05
+7.10%
6.08%US$405.00US$323.00n/a24
Apr ’26US$331.43
US$362.55
+9.39%
6.01%US$405.00US$323.00n/a24
Mar ’26US$304.73
US$362.31
+18.89%
5.92%US$405.00US$323.00n/a24
Feb ’26US$294.98
US$370.25
+25.52%
6.59%US$438.00US$325.00n/a24
Jan ’26US$276.41
US$395.73
+43.17%
5.53%US$438.00US$344.78n/a24
Dec ’25US$337.80
US$399.00
+18.12%
4.42%US$438.00US$360.00n/a24
Nov ’25US$316.02
US$397.84
+25.89%
4.63%US$438.00US$355.00US$244.2224
Oct ’25US$349.81
US$398.29
+13.86%
4.92%US$438.00US$355.00US$292.4724
Sep ’25US$360.40
US$395.86
+9.84%
4.83%US$438.00US$355.00US$301.6524
Aug ’25US$337.64
US$394.36
+16.80%
5.09%US$435.00US$349.00US$258.1924
Jul ’25US$326.97
US$392.79
+20.13%
5.20%US$435.00US$349.00US$335.1025
Jun ’25US$337.76
US$392.04
+16.07%
5.39%US$435.00US$349.00US$318.1123
May ’25US$358.06
US$381.44
+6.53%
7.24%US$432.00US$292.10US$338.9923
Apr ’25US$364.09
US$376.83
+3.50%
6.51%US$410.00US$292.10US$331.4323
Mar ’25US$332.43
US$369.10
+11.03%
6.33%US$400.00US$292.10US$304.7321
Feb ’25US$307.37
US$355.20
+15.56%
6.05%US$385.00US$292.10US$294.9821
Jan ’25US$299.20
US$348.91
+16.61%
6.37%US$385.00US$292.10US$276.4121
Dec ’24US$269.93
US$350.00
+29.66%
5.51%US$385.00US$321.00US$337.8021
Nov ’24US$310.97
US$335.18
+7.79%
7.74%US$385.00US$287.00US$316.0222
US$341.34
Fair Value
23.0% undervalued intrinsic discount
23
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/07 19:40
End of Day Share Price 2025/11/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

The Cigna Group is covered by 41 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Hua HaBaird
Andrew MokBarclays